Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01022255
Other study ID # PMP0025-01
Secondary ID
Status Completed
Phase Phase 1
First received November 30, 2009
Last updated January 29, 2014
Start date January 2010
Est. completion date October 2013

Study information

Verified date January 2014
Source Icon Genetics GmbH
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This phase I study will evaluate the safety and tolerability of an autologous idiotype vaccine manufactured by magnICON technology for patients with relapsed follicular lymphoma who are in complete or partial remission following non-antiCD20 containing salvage therapy. Data in terms of idiotype-specific immune responses will also be obtained.


Recruitment information / eligibility

Status Completed
Enrollment 28
Est. completion date October 2013
Est. primary completion date October 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Subjects with histologically proven follicular lymphoma (grade 1, 2, or 3a), in clinical relapse/progression requiring treatment

- Subjects must have had first line treatment consisting of rituximab with or without rituximab maintenance therapy (i.e. rituximab monotherapy, R-CHOP, R-CVP, R-FND, etc)

- At least 4 months since last rituximab exposure

- Subjects may have had any number of prior treatment regimens. If enrolled with transformed follicular lymphoma, study subject must have had anthracycline in a previous regimen

- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

- Life expectancy of at least 12 months

- Presence of at least a 2x2 cm in diameter lymph node (either a single lymph node or combined volume of lymphoid tissue) accessible for excision; for histological confirmation of diagnosis and for manufacture of the vaccine

- Measurable disease in neck, chest, abdomen, or pelvis as assessed by computed tomography (CT) scan such that response to 2nd line chemotherapy can be defined by the criteria of Cheson et al (JCO 2007; 25:579, see appendix 15.2 and ref 65). PET scan results are not required for enrollment

Exclusion Criteria:

- Exposure to rituximab or antiCD-20 directed therapy within the 4 months prior to enrollment

- History of human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection

- Active clinically serious infections (> grade 2 National Cancer Institute Common Toxic Criteria [NCI-CTC] version 3.0)

- Symptomatic metastatic brain or meningeal tumors including lymphoma unless the patient is > 6 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry

- History of organ allograft

- Patients undergoing renal dialysis

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Biological:
Autologous FL vaccine
1.0 mg of vaccine subcutaneously (s.c.) on Day 1, and followed by 125 µg GM-CSF s.c. at Day 1 -4, monthly until 8th vaccination, bimonthly until 12th vaccination (month 16)

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Icon Genetics GmbH

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of patients with toxicities as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI/CTCAE) version 3.0 grade >/= 3 to the magnICON generated idiotype (Id) vaccine One month after sixth vaccination (=7 month after achievement of tumour remission and recovery of normal blood values) Yes
Secondary Assessment of humoral idiotype-specific immune responses One month after sixth vaccination (=7 month after achievement of tumour remission and recovery of normal blood values) No
Secondary Assessment of cellular idiotype-specific immune responses One month after sixth vaccination (=7 month after achievement of tumour remission and recovery of normal blood values) No
Secondary Long-term safety/tolerability as determined by the proportion of patients with toxicities as assessed by the FDA CBER Guidance for Industry Toxicity Grading Scale in Preventive Vaccine Clinical Trials and the NCI/CTCAE version 4.02 grade >/= 3 Up to the conclusion of a 12 cycle vaccination phase (month 16) Yes
See also
  Status Clinical Trial Phase
Completed NCT01950273 - Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma Phase 1
Completed NCT00930514 - A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma Phase 1
Completed NCT02472756 - Open, Noninterventional Trial of MabThera in Combination With Chemotherapy (CVP, CHOP or FCM) in Patients With Relapsed/Refractory Follicular Lymphoma N/A
Withdrawn NCT00319332 - A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen Phase 3
Completed NCT00193492 - A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma Phase 2
Withdrawn NCT00092274 - Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma Phase 1/Phase 2
Completed NCT03087929 - Follow-up Trial of Rituximab Interferon Transplant Trial: Study Drug-Rituximab and Alpha Interferon N/A
Terminated NCT02413489 - An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma Phase 2
Completed NCT00915096 - Positron Emission Tomography (PET)-Scan in the Evaluation of High Tumor Burden Follicular Lymphoma
Recruiting NCT05849857 - Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries Phase 2
Recruiting NCT05410418 - Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma Phase 2
Terminated NCT01609036 - An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Lymphoma N/A
Completed NCT01234766 - Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma Phase 2
Completed NCT00849147 - Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603) Phase 2
Terminated NCT00384111 - Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL) Phase 3
Completed NCT03682796 - Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma Phase 1
Recruiting NCT04982471 - Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study
Active, not recruiting NCT02996773 - Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine Phase 1
Terminated NCT00562965 - Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL) Phase 3
Active, not recruiting NCT00317096 - FCM Versus R-FCM Followed by R-Maintenance or Observation Only Phase 3